Related references
Note: Only part of the references are listed.PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake
Lisa K. Dunnwald et al.
CLINICAL CANCER RESEARCH (2011)
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
David Groheux et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments
Ronald Boellaard
JOURNAL OF NUCLEAR MEDICINE (2011)
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
Jorma J. de Ronde et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy A Single Institutional Experience With 359 Cases
Rohit Bhargava et al.
CANCER (2010)
Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer
Jennifer M. Specht et al.
CLINICAL CANCER RESEARCH (2010)
18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis
Joseph R. Osborne et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET
Michal E. Schneider-Kolsky et al.
BREAST CANCER RESEARCH (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F] Fluorodeoxyglucose
Joerg Schwarz-Dose et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Silvia Darb-Esfahani et al.
BREAST CANCER RESEARCH (2009)
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters
Sandip Basu et al.
CANCER (2008)
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease
Julie R. Gralow et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Alfredo Berruti et al.
ONCOLOGIST (2008)
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
Alina Berriolo-Riedinger et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions
Ayse Mavi et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN(A)-1 trial
Bruno P. Coudert et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
被撤回的出版物: Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial (Retracted Article. See vol 12, pg 116, 2011)
[Anonymous]
LANCET ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography
Caroline Rousseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer:: results of a multicenter phase II trial
BP Coudert et al.
ANNALS OF ONCOLOGY (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer:: 10-year follow-up results of The French Adjuvant Study Group 05 randomized trial
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
D Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer
P Fumoleau et al.
SEMINARS IN ONCOLOGY (2004)
Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors:: A study of preoperative treatment
M Colleoni et al.
CLINICAL CANCER RESEARCH (2004)
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
SJ Kim et al.
ANNALS OF ONCOLOGY (2004)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma:: comparison with biochemical determination in a prospective study of 793 cases
B Zafrani et al.
HISTOPATHOLOGY (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
